How tiny chemical tweaks reshape cannabinoid receptor signals
Side-Chain Homologs of Δ9-THC, Δ8-THC, and HHC Reveal Pathway Bias at CB1R and CB2R Cannabinoid Receptors.
AI Summary
This laboratory study examined how structural changes to Δ9-THC, Δ8-THC, and HHC affect signaling through the CB1R and CB2R cannabinoid receptors. Researchers varied the alkyl side-chain length from C3 to C8, changed the double-bond position, and compared the 9R and 9S forms of HHC in engineered human cells. They measured several G protein and β-arrestin signaling pathways rather than treating receptor activation as a single response.
The strongest pattern was linked to side-chain length: C4–C8 compounds acted as high-efficacy agonists in Gi/o pathways but only partial agonists in β-arrestin recruitment, with signaling potency generally increasing through the C7–C8 compounds. By contrast, C3 compounds showed little agonist activity and behaved as functional CB1R antagonists. Matched 9R-HHC compounds were more potent than 9S-HHC compounds. These are cell-based receptor findings—not evidence that particular cannabis products will produce predictable effects in people—but they may help guide the design and evaluation of emerging cannabinoid products.
💡 Key Findings
📄
Original Abstract
Related Research
Similar Studies
More THC research papers you might find interesting.
Small lab study finds cannabis affected simulated driving and confidence
A lab method measures 17 cannabinoids across five hemp product types
A single-center study finds varied care and no recurrence in follow-up
Explore More Research
Stay informed about the latest cannabis science.